BioSyent Announces the Availability of Gelclair® in Canada
20. November 2023 08:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the...
BioSyent Releases Q3 and YTD 2023 Financial Results
16. November 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended...
BioSyent Declares Fourth Quarter 2023 Dividend
15. November 2023 16:34 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 15, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent Schedules Q3 and YTD 2023 Earnings Release for November 16, 2023
09. November 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 09, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended...
BioSyent Launches "menopauseinformation.ca" on World Menopause Day
18. Oktober 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce the launch of menopauseinformation.ca, a comprehensive online platform...
BioSyent Releases Q2 and H1 2023 Financial Results
22. August 2023 16:15 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2023. Key...
BioSyent Declares Third Quarter 2023 Dividend
22. August 2023 16:01 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent Schedules Q2 and H1 2023 Earnings Release for August 22, 2023
15. August 2023 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 15, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30,...
BioSyent lance Inofolic® pour les femmes atteintes du syndrome des ovaires polykystiques (SOPK)
08. August 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, 08 août 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », titre à la Bourse de croissance TSX : RX) a le plaisir d’annoncer que sa filiale, BioSyent Pharma Inc., a...
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
08. August 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first...